Important reforms to the litigation funding regime in England and Wales came into force on 1 April 2013. The claimant lawyer bar has warned that the reforms are likely to seriously impact on the viability of group product liability claims in future, due to the reduction in financial incentive for claimant lawyers to pursue such claims. This article looks at whether this is likely to be the case, or whether the various changes will mean that defendants are in fact more likely to face group claims in the future.

This article is part of the PLC multi-jurisdictional guide to life sciences. For a full list of jurisdictional Q&As visit www.practicallaw.com/lifesciences-mjg.